Breaking News

Financial Report: AbbVie

July 26, 2013

Revenues up 4% in the quarter, driven by Humira

2Q Revenues: $4.7 billion (+4%)

2Q Earnings: $1.1 billion (-16%)

YTD Revenues: $9.0 billion (+4%)

YTD Earnings: $2.0 billion (-5%)

Comments: Humira sales were up 12% to $2.6 billion in the quarter. Kaletra sales were $278 million, up 1%. TriCor/Trilipix sales were down 66% to $107 million due to loss of exclusivity. Niaspan sales were up 10% to $232 million. Synthroid sales were up 24% to $153 million. Zemplar sales were up 13% to $107 million, and Creon sales were up 21% to $106 million.
blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors